Skip to main content

Free Content Delayed sleep phase syndrome: A placebo-controlled cross-over study on the effects of melatonin administered five hours before the individual dim light melatonin onset

Download Article:

The full text article is temporarily unavailable.

We apologise for the inconvenience. Please try again later.

In a double-blind placebo-controlled cross-over study, 30 patients with Delayed Sleep Phase Syndrome (DSPS) were included, of whom 25 finished the study. Melatonin 5 mg was administered during two weeks in a double-blind setting and two weeks in an open setting successively or interrupted by two weeks of placebo. The study's impact was assessed by measurements of the 24-h curves of endogenous melatonin production and rectal temperature (n=14), polysomnography (n=22), actigraphy (n=13), sleep log (n=22), and subjective sleep quality (n=25). Mean dim light melatonin onset (DLMO) (±SD), before treatment, occurred at 23.17 hours (±138 min). Melatonin was administered five hours before the individual DLMO. After treatment, the onset of the nocturnal melatonin profile was significantly advanced by approximately 1.5 hour. Body temperature trough did not advance significantly. During melatonin use, actigraphy showed a significant advance of sleep onset and polysomnography, a significant decreased sleep latency. Sleep architecture was not influenced. During melatonin treatment patients felt significantly more refreshed in the morning. These results show that analysis of DLMO of patients suffering from DSPS is important both for diagnosis and therapy. These results are discussed in terms of the biochemistry of the pineal.
No References
No Citations
No Supplementary Data
No Data/Media
No Metrics

Keywords: body temperature, delayed sleep phase syndrome (ds

Document Type: Research Article

Affiliations: 1: Department of Clinical Pharmacy, Department of Neurology, Leiden University Medical Centre 2: Department of Clinical Pharmacy, Hospital `De Gelderse Vallei', P.O. Box 9501, 6720 GA Bennekom, The Netherlands 3: Department of Clinical Pharmacy, Department of Clinical Chemistry, Leiden University Medical Centre 4: Department of Clinical Pharmacy, Department of Physiology, Leiden University Medical Centre, The Netherlands

Publication date: 1998-06-01

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more